[HTML][HTML] Apatinib ameliorates doxorubicin-induced migration and cancer stemness of osteosarcoma cells by inhibiting Sox2 via STAT3 signalling
ZC Tian, JQ Wang, H Ge - Journal of Orthopaedic Translation, 2020 - Elsevier
Background Osteosarcoma, ranking as the second primary cause of cancer-related death, is
the most common type of bone cancer. Doxorubicin (DOX) is used as a first-line treatment for …
the most common type of bone cancer. Doxorubicin (DOX) is used as a first-line treatment for …
[HTML][HTML] Evaluation of safety and efficacy of apatinib combination with chemotherapy for ovarian cancer treatment: a systematic review and meta-analysis
J Qi, E Liu, H Yue, G Chen, Y Liu… - Annals of Palliative …, 2021 - apm.amegroups.org
Background: Apatinib in combination with chemotherapy (CT) has been used in the
treatment of ovarian cancer (OC), however, the safety and efficacy are unclear. The study …
treatment of ovarian cancer (OC), however, the safety and efficacy are unclear. The study …
[HTML][HTML] Safety and effectiveness of apatinib in patients with previously treated metastatic gastric cancer: a sub-analysis from the real-world study of apatinib for gastric …
X Wang, J Yu, M Yang, L Liu, J Gao, Y Ren… - American Journal of …, 2020 - ncbi.nlm.nih.gov
Apatinib, a VEGFR2 receptor tyrosine kinase inhibitor, showed survival benefits in Asian
patients with heavily pretreated advanced gastric cancer. However, the adverse event (AEs) …
patients with heavily pretreated advanced gastric cancer. However, the adverse event (AEs) …
Efficacy and safety of low‐dose apatinib in ovarian cancer patients with platinum‐resistance or platinum‐refractoriness: a single‐center retrospective study
W Chen, Z Li, Z Zheng, X Wu - Cancer medicine, 2020 - Wiley Online Library
Background This study aimed to evaluate the efficacy and safety of apatinib with a low dose
of 250 mg/d in the treatment of platinum‐resistant or platinum‐refractory ovarian cancer …
of 250 mg/d in the treatment of platinum‐resistant or platinum‐refractory ovarian cancer …
Safety and efficacy of low-dosage apatinib monotherapy in advanced lung squamous-cell carcinoma: a prospective cohort study
Q Geng, H Shen, W Zhu, Y Lu, M Wang… - OncoTargets and …, 2020 - Taylor & Francis
Background Lung squamous-cell carcinoma (SqCC) is the second most common histology
in non-small-cell lung carcinomas (NSCLCs). The treatment options for advanced lung …
in non-small-cell lung carcinomas (NSCLCs). The treatment options for advanced lung …
Continuous low-dose apatinib combined with WBRT significantly reduces peritumoral edema and enhances the efficacy of symptomatic multiple brain metastases in …
Y Ren, SB Wang, L Zhou, SQ Liu… - … in Cancer Research …, 2021 - journals.sagepub.com
Background: Symptomatic multiple brain metastases with peritumoral brain edema (PTBE)
occur in non-small cell lung cancer patients (NSCLC) who are without driver mutations or …
occur in non-small cell lung cancer patients (NSCLC) who are without driver mutations or …
Efficacy and safety of apatinib or apatinib combined with etoposide in patients with biochemical recurrent platinum-resistance/refractoriness ovarian cancer: A …
J Wu, Q Guo, Y Wu, S Wang, X Wu, X Ju - 2022 - researchsquare.com
Background Although apatinib or apatinib combined with etoposide has been widely used in
the treatment of platinum-resistant or refractory ovarian cancer (OC), certain effects have …
the treatment of platinum-resistant or refractory ovarian cancer (OC), certain effects have …
Secondary cavitary pulmonary tuberculosis after apatinib treatment in lung squamous cell cancer
W Zhang, Y Liu, D Zeng - American Journal of Therapeutics, 2020 - journals.lww.com
2657-2665. 2. Allegra A, Penna G, Alonci A, et al. Monoclonal antibodies: potential new
therapeutic treatment against multiple myeloma. Eur J Haematol. 2013; 90: 441-468. 3 …
therapeutic treatment against multiple myeloma. Eur J Haematol. 2013; 90: 441-468. 3 …
Low-Dosage Apatinib as Rescuing Treatment in Advanced Malignant Pleural Mesothelioma
Y Liu, W Zhang, D Zeng - American Journal of Therapeutics, 2020 - journals.lww.com
To the Editor: Malignant pleural mesothelioma (MPM) is the most common type of malignant
mesothelioma. 1 Few drugs could be selected for MPM therapy except for platinum adding …
mesothelioma. 1 Few drugs could be selected for MPM therapy except for platinum adding …